Fig. 6From: Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomasSiglec-15+ tumor cells or TAMs reversed CD8+ T cells prognosis value, and enhanced the prognosis value of Tregs and TAMs. A Kaplan–Meier survival analysis showed that CD8+ T cells localized to S15− tumor cells had no prognostic significance (P = 0.162). B CD8+ T cells localized to S15+ tumor cells had an adverse effect on prognosis (P = 0.008). C CD8+ T cells predominantly localized to S15− TAMs demonstrated a favorable effect on prognosis (P = 0.038). D CD8+ T cells predominantly localized to S15+ TAMs tend to have an adverse effect on prognosis (P = 0.057). E CD4+FoxP3+ Tregs surrounding S15− tumor cells were associated with a bad prognosis (P = 0.035). F CD4+FoxP3+ Tregs surrounding S15+ tumor cells were correlated with poor outcome (P = 0.008). G CD4+FoxP3+ Tregs predominantly localized to S15− TAMs had no effect on patient's survival (P = 0.117). H CD4+FoxP3+ Tregs predominantly localized to S15+ TAMs had an adverse effect on prognosis (P = 0.026). I CD68+ TAMs surrounding S15− tumor cells had no significant effect on the prognosis (P = 0.088). J CD68+ TAMs predominantly localized to S15+ tumor cells demonstrated an adverse effect on prognosis (P = 0.026). K Univariate Cox regression analysis demonstrated that Siglec-15 do work as a risk factor associated with the prognosis of these immune cellsBack to article page